Characterization of a Tumor-Associated Activating Mutation of the p110β PI 3-Kinase

Hashem A. Dbouk, Bassem D. Khalil, Haiyan Wu, Aliaksei Shymanets, Bernd Nürnberg, Jonathan M. Backer

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The PI3-kinase pathway is commonly activated in tumors, most often by loss of PTEN lipid phosphatase activity or the amplification or mutation of p110α. Oncogenic mutants have commonly been found in p110α, but rarely in any of the other catalytic subunits of class I PI3-kinases. We here characterize a p110β helical domain mutation, E633K, first identified in a Her2-positive breast cancer. The mutation increases basal p110β activity, but does not affect activation of p85/p110β dimers by phosphopeptides or Gβγ. Expression of the mutant causes increases in Akt and S6K1 activation, transformation, chemotaxis, proliferation and survival in low serum. E633 is conserved among class I PI3 Ks, and its mutation in p110β is also activating. Interestingly, the E633K mutant occurs near a region that interacts with membranes in activated PI 3-kinases, and its mutation abrogates the requirement for an intact Ras-binding domain in p110β-mediated transformation. We propose that the E633K mutant activates p110β by enhancing its basal association with membranes. This study presents the first analysis of an activating oncogenic mutation of p110β.

Original languageEnglish (US)
Article numbere63833
JournalPLoS One
Volume8
Issue number5
DOIs
StatePublished - May 29 2013

Fingerprint

phosphatidylinositol 3-kinase
Phosphatidylinositol 3-Kinases
Tumors
mutation
Mutation
neoplasms
Chemical activation
Membranes
Phosphopeptides
Neoplasms
mutants
Phosphoric Monoester Hydrolases
Dimers
Amplification
phosphotransferases (kinases)
Association reactions
PTEN Phosphohydrolase
Lipids
chemotaxis
Chemotaxis

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Characterization of a Tumor-Associated Activating Mutation of the p110β PI 3-Kinase. / Dbouk, Hashem A.; Khalil, Bassem D.; Wu, Haiyan; Shymanets, Aliaksei; Nürnberg, Bernd; Backer, Jonathan M.

In: PLoS One, Vol. 8, No. 5, e63833, 29.05.2013.

Research output: Contribution to journalArticle

Dbouk, Hashem A. ; Khalil, Bassem D. ; Wu, Haiyan ; Shymanets, Aliaksei ; Nürnberg, Bernd ; Backer, Jonathan M. / Characterization of a Tumor-Associated Activating Mutation of the p110β PI 3-Kinase. In: PLoS One. 2013 ; Vol. 8, No. 5.
@article{e7d802715fbb45d1b1e8e366cc6db934,
title = "Characterization of a Tumor-Associated Activating Mutation of the p110β PI 3-Kinase",
abstract = "The PI3-kinase pathway is commonly activated in tumors, most often by loss of PTEN lipid phosphatase activity or the amplification or mutation of p110α. Oncogenic mutants have commonly been found in p110α, but rarely in any of the other catalytic subunits of class I PI3-kinases. We here characterize a p110β helical domain mutation, E633K, first identified in a Her2-positive breast cancer. The mutation increases basal p110β activity, but does not affect activation of p85/p110β dimers by phosphopeptides or Gβγ. Expression of the mutant causes increases in Akt and S6K1 activation, transformation, chemotaxis, proliferation and survival in low serum. E633 is conserved among class I PI3 Ks, and its mutation in p110β is also activating. Interestingly, the E633K mutant occurs near a region that interacts with membranes in activated PI 3-kinases, and its mutation abrogates the requirement for an intact Ras-binding domain in p110β-mediated transformation. We propose that the E633K mutant activates p110β by enhancing its basal association with membranes. This study presents the first analysis of an activating oncogenic mutation of p110β.",
author = "Dbouk, {Hashem A.} and Khalil, {Bassem D.} and Haiyan Wu and Aliaksei Shymanets and Bernd N{\"u}rnberg and Backer, {Jonathan M.}",
year = "2013",
month = "5",
day = "29",
doi = "10.1371/journal.pone.0063833",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

TY - JOUR

T1 - Characterization of a Tumor-Associated Activating Mutation of the p110β PI 3-Kinase

AU - Dbouk, Hashem A.

AU - Khalil, Bassem D.

AU - Wu, Haiyan

AU - Shymanets, Aliaksei

AU - Nürnberg, Bernd

AU - Backer, Jonathan M.

PY - 2013/5/29

Y1 - 2013/5/29

N2 - The PI3-kinase pathway is commonly activated in tumors, most often by loss of PTEN lipid phosphatase activity or the amplification or mutation of p110α. Oncogenic mutants have commonly been found in p110α, but rarely in any of the other catalytic subunits of class I PI3-kinases. We here characterize a p110β helical domain mutation, E633K, first identified in a Her2-positive breast cancer. The mutation increases basal p110β activity, but does not affect activation of p85/p110β dimers by phosphopeptides or Gβγ. Expression of the mutant causes increases in Akt and S6K1 activation, transformation, chemotaxis, proliferation and survival in low serum. E633 is conserved among class I PI3 Ks, and its mutation in p110β is also activating. Interestingly, the E633K mutant occurs near a region that interacts with membranes in activated PI 3-kinases, and its mutation abrogates the requirement for an intact Ras-binding domain in p110β-mediated transformation. We propose that the E633K mutant activates p110β by enhancing its basal association with membranes. This study presents the first analysis of an activating oncogenic mutation of p110β.

AB - The PI3-kinase pathway is commonly activated in tumors, most often by loss of PTEN lipid phosphatase activity or the amplification or mutation of p110α. Oncogenic mutants have commonly been found in p110α, but rarely in any of the other catalytic subunits of class I PI3-kinases. We here characterize a p110β helical domain mutation, E633K, first identified in a Her2-positive breast cancer. The mutation increases basal p110β activity, but does not affect activation of p85/p110β dimers by phosphopeptides or Gβγ. Expression of the mutant causes increases in Akt and S6K1 activation, transformation, chemotaxis, proliferation and survival in low serum. E633 is conserved among class I PI3 Ks, and its mutation in p110β is also activating. Interestingly, the E633K mutant occurs near a region that interacts with membranes in activated PI 3-kinases, and its mutation abrogates the requirement for an intact Ras-binding domain in p110β-mediated transformation. We propose that the E633K mutant activates p110β by enhancing its basal association with membranes. This study presents the first analysis of an activating oncogenic mutation of p110β.

UR - http://www.scopus.com/inward/record.url?scp=84878471601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878471601&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0063833

DO - 10.1371/journal.pone.0063833

M3 - Article

C2 - 23734178

AN - SCOPUS:84878471601

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

M1 - e63833

ER -